Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve‐Induced Thrombin Generation
Open Access
- 25 August 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 4 (8), e002322
- https://doi.org/10.1161/jaha.115.002322
Abstract
Background Patients with mechanical heart valves (MHV) require warfarin to prevent thromboembolism. Although dabigatran was as effective as warfarin for stroke prevention in atrial fibrillation when compared with warfarin in patients with MHV, the study was stopped early because of more strokes and bleeding with dabigatran. To determine why dabigatran was less effective than warfarin, we compared their effects on thrombin generation induced by MHV. Methods and Results Thrombin generation in the absence or presence of valve leaflets or sewing ring segments (SRS) was quantified. Studies were done in control plasma, plasma depleted of factors (F) XII, XI, or VII, plasma containing varying concentrations of dabigatran, or plasma from patients on dabigatran or warfarin with varying dabigatran concentrations or international normalized ratio (INR) values. Mean endogenous thrombin potential (ETP) increased 1.2‐, 1.5‐, and 1.8‐fold in the presence of leaflets, Teflon SRS, and Dacron SRS, respectively. Whereas ETP in FVII‐depleted and control plasma was similar, ETP was reduced to background levels in FXII‐depleted plasma and abrogated in FXI‐depleted plasma. Dabigatran had little effect on ETP at concentrations below 400 ng/mL, whereas in plasma from warfarin‐treated patients, ETP was suppressed with INR values over 1.5. Conclusions MHV induce thrombin generation via the intrinsic pathway and generate sufficient thrombin to overwhelm clinically relevant dabigatran concentrations. In contrast, warfarin is more effective than dabigatran at suppressing MHV‐induced thrombin generation. These data explain why dabigatran failed in MHV patients and suggest that strategies targeting FXII or FXI may suppress the root cause of thrombosis in such patients.This publication has 31 references indexed in Scilit:
- Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valvesThe Journal of Thoracic and Cardiovascular Surgery, 2011
- A role for factor XIIa–mediated factor XI activation in thrombus formation in vivoBlood, 2010
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- In-Vitro Localization of Initial Flow-Induced Thrombus Formation in Bileaflet Mechanical Heart ValvesASAIO Journal, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Factor XI–dependence of surface- and tissue factor–initiated thrombus propagation in primatesBlood, 2003
- Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart ValvesThe New England Journal of Medicine, 1995
- Oral Anticoagulant DrugsThe New England Journal of Medicine, 1991